文献速递白血病

menin 抑制剂 revumenib 治疗 KMT2A 重排复发或难治性急性白血病(AUGMENT-101)

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
PubMed 文献 · J Clin Oncol · 2024-08-09

AUGMENT-101 是一项 I/II 期开放标签剂量递增和扩展研究,在五个国家 22 个临床中心开展,评估 revumenib 在复发/难治性 KMT2A 重排急性白血病患者中的疗效与安全性。II 期注册部分共治疗 94 例患者,可评估疗效的 57 例中完全缓解或伴部分血液学恢复的完全缓解率为 22.8%(95%CI 12.7-35.8),超过 10% 的无效假设(P=0.0036),总缓解率 63.2%(95%CI 49.3-75.6)。

要点

  • 可评估疗效的 57 例中 CR+CRh 率为 22.8%(95%CI 12.7-35.8),超过 10% 的无效假设(P=0.0036)。
  • 总缓解率为 63.2%(95%CI 49.3-75.6),22 例缓解者中 15 例(68.2%)无可检测残留病。
  • ≥3 级不良事件包括发热性中性粒细胞减少(37.2%)、分化综合征(16.0%)和 QTc 延长(13.8%)。

核心结论

  • revumenib 在复发/难治性 KMT2A 重排急性白血病中取得高缓解率,安全性特征可预测。
  • 据作者所知,该试验是针对这些患者靶向治疗的最大规模评估。

研究设计与样本

  • AUGMENT-101 为 I/II 期、开放标签、剂量递增和扩展研究,在五个国家 22 个临床中心开展(ClinicalTrials.gov 标识号 NCT04065399)。
  • 报告的是 II 期注册部分结果。
  • 入组年龄≥30 天、复发/难治性 KMT2A 重排急性白血病或伴核磷蛋白 1(NPM1)突变的 AML 患者。
  • revumenib 每 12 小时给药一次,剂量 163 mg(体重<40 kg 时 95 mg/m2),联用强效细胞色素 P450 抑制剂,28 天为一周期。
  • 主要终点为完全缓解(CR)或伴部分血液学恢复的完全缓解(CR+CRh)率以及安全性。

主要发现

  • 2021年10月1日至2023年7月24日,共治疗 N=94 例患者(中位[范围]年龄 37[1.3-75]岁)。
  • ≥3 级不良事件包括发热性中性粒细胞减少(37.2%)、分化综合征(16.0%)和 QTc 延长(13.8%)。
  • 可评估疗效的患者(n=57)中,CR+CRh 率为 22.8%(95%CI 12.7-35.8),超过 10% 的无效假设(P=0.0036)。
  • 总缓解率为 63.2%(95%CI 49.3-75.6),22 例缓解者中 15 例(68.2%)无可检测残留病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with KMT2A-rearranged (KMT2Ar) acute leukemia. Here, we evaluated the activity of revumenib in individuals with relapsed/refractory (R/R) KMT2Ar acute leukemia. METHODS: AUGMENT-101 is a phase I/II, open-label, dose-escalation and expansion study of revumenib conducted across 22 clinical sites in five countries (ClinicalTrials.gov identifier: NCT04065399). We report results from the phase II, registration-enabling portion. Individuals age ≥30 days with R/R KMT2Ar acute leukemia or with AML and nucleophosmin 1 (NPM1) mutation were enrolled. Revumenib was administered once every 12 hours, at 163 mg (95 mg/m2 if weight <40 kg) with a strong cytochrome P450 inhibitor, in 28-day cycles. The primary end points were the rate of complete remission (CR) or CR with partial hematologic recovery (CR + CRh) and safety. At a prespecified interim analysis, safety was assessed in all KMT2Ar treated patients; efficacy was assessed in those with centrally confirmed KMT2Ar. The separate NPM1 cohort of the trial is ongoing. RESULTS: From October 1, 2021, to July 24, 2023, N = 94 patients (median [range] age, 37 [1.3-75] years) were treated. Grade ≥3 adverse events included febrile neutropenia (37.2%), differentiation syndrome (16.0%), and QTc prolongation (13.8%). In the efficacy-evaluable patients (n = 57), the CR + CRh rate was 22.8% (95% CI, 12.7 to 35.8), exceeding the null hypothesis of 10% (P = .0036). Overall response rate was 63.2% (95% CI, 49.3 to 75.6), with 15 of 22 patients (68.2%) having no detectable residual disease. CONCLUSION: Revumenib led to high remission rates with a predictable safety profile in R/R KMT2Ar acute leukemia. To our knowledge, this trial represents the largest evaluation of a targeted therapy for these patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Issa GC, Aldoss I, Thirman MJ, et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2024. PMID: 39121437. doi:10.1200/JCO.24.00826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。